Brief: Renovorx Announces New Positive Interim Late-Stage Data For Cancer Treatment
29/06/2023 13:16
June 29 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ANNOUNCES NEW POSITIVE INTERIM PHASE III DATA
DEMONSTRATING RENOVOGEM™ DELAYS CANCER PROGRESSION BY EIGHT
MONTHS IN LOCALLY ADVANCED PANCREATIC CANCER
* RENOVORX- SIX-MONTH OVERALL SURVIVAL BENEFIT WITH
RENOVOGEM
VERSUS SYSTEMIC CHEMOTHERAPY; 65% REDUCTION IN ADVERSE EFFECTS
Source text for Eikon: ID:nBw4lDZ4ga
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer